H.C. Wainwright assumed coverage of Evotec (EVO) with a Buy rating and $7 price target The company’s has transformed from a legacy asset-heavy integrated model toward a leaner and capital-efficient structure, the analyst tells investors in a research note. The firm sees current share levels as an attractive entry point for a long-term investor.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVO:
- Evotec appoints Ingrid Muller as COO
- Limited Near-Term Visibility and Execution Risk Drive Sell Rating on Evotec Despite In-Line Results
- Evotec Earnings Call: Biologics Surge Amid Tough Reset
- Evotec Posts Strong 2025 Results and Accelerates Horizon Transformation With Major Biologics Deals
- Evotec Names New Supervisory Board Chair and Expects $100 Million Windfall From Tubulis Deal